TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion–Induced Myocardial Ferroptosis
Circulation · 28.04.2026 · 153 (17) · 1314-1336
DOI: 10.1161/circulationaha.125.077782 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 28.04.2026. Verfasst von Kun Zhu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cardiovascular Science, Beijing Clinical Research Institute (K.Z., J.G., Y. Liu, J.L., X.W., R.D., L.G., J.B., R.C., Z.L., W.Z., Y.Z., …. Hauptthemen laut MEDLINE: Ferroptosis, Myocardial Reperfusion Injury, Tripartite Motif-Containing Protein 28, Myocytes, Cardiac. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Myocardial ischemia/reperfusion (I/R) injury is a common and severe clinical complication in patients with ischemic heart disease after reperfusion therapy. Effective therapeutic strategies for myocardial I/R injury remain limited. Ferroptosis is a form of regulated cell death characterized by iron-dependent lipid peroxidation. However, the mechanisms underlying ferroptosis in myocardial I/R injury are not fully understood. METHODS: Transcriptomic data from patients with heart failure and cardiomyocytes undergoing ferroptosis were analyzed. Based on the screening results, TRIM28 (tripartite motif-containing 28) expression was evaluated in ferroptotic cardiomyocytes. Cardiac I/R injury models in mice and hypoxia/reoxygenation injury models in neonatal rat ventricular myocytes were established. To explore the function of TRIM28, we used adeno-associated virus serotype 9 to achieve cardiomyocyte-specific overexpression and generated tamoxifen-inducible cardiomyocyte–specific TRIM28 knockout mice. RNA sequencing, coimmunoprecipitation coupled with mass spectrometry, and ubiquitinome profiling were applied to elucidate the underlying mechanisms. Human heart samples from patients with ischemic heart disease were used to evaluate the expression of TRIM28 and its related signaling molecules. The Connectivity Map database was used to screen potential activators of TRIM28. RESULTS: We found that TRIM28 expression was downregulated in ferroptosis inducer–treated and hypoxia/reoxygenation–injured cardiomyocytes, as well as in I/R-injured mouse hearts. Cardiomyocyte-specific overexpression of TRIM28 protected the heart against I/R-induced ferroptosis, whereas its deficiency exacerbated myocardial I/R-induced ferroptotic injury. Mechanistically, TRIM28 functioned as an E3 ubiquitin ligase that directly bound to IRP2 (iron regulatory protein 2) and promoted K48-linked ubiquitination at the K877 site, leading to the downregulation of IRP2 and TFR1 (transferrin receptor 1), suppression of intracellular iron uptake, and consequent attenuation of cardiomyocyte ferroptosis. Furthermore, p55γ interacted with and upregulated TRIM28, thereby mitigating I/R-induced myocardial ferroptosis. Consistent with these findings, protein levels of TRIM28 and p55γ were decreased in heart samples from patients with ischemic heart disease, whereas IRP2 and TFR1 were increased. Last, we demonstrated that perhexiline inhibited I/R-induced myocardial ferroptosis by upregulating p55γ and TRIM28. CONCLUSIONS: Our study identifies TRIM28 as an essential E3 ubiquitin ligase of IRP2 and delineates that TRIM28-mediated inhibition of myocardial ferroptosis by targeting IRP2-TFR1 signaling protects the heart against I/R injury, indicating that targeting TRIM28 represents a promising therapeutic strategy for suppressing cardiomyocyte ferroptosis and I/R injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Cardiovascular Science, Beijing Clinical Research Institute (K.Z., J.G., Y. Liu, J.L., X.W., R.D., L.G., J.B., R.C., Z.L., W.Z., Y.Z., Y.W., L.D., Y. Li, D.-S.L., W.A., C.-M.C.), Beijing Friendship Hospita…
- Division of Cardiovascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.W., D.J.).
- Key Laboratory of Organ Transplantation, Ministry of Education, Chinese Academy of Medical Sciences, National Health Commission Key Laboratory of Organ Transplantation, Wuhan, China (X.W., D.J.).
- Department of Biomedical Informatics, Center for Noncoding RNA Medicine, State Key Laboratory of Vascular Homeostasis and Remodeling, School of Basic Medical Sciences, Peking University, Beijing, China (Q.C.).
- Department of Cardiology (W.L.), Beijing Friendship Hospital, Capital Medical University, China.
ORCID-Profile: Kun Zhu, Yangli Liu, Jingchen Li, Xun Wang, Rilei Dai, Dingsheng Jiang, Le Gao, Jiaxing Bai, Rui Cao, Zhiheng Lin, Wei Zhou, Yifan Zhuang, Yufei Wang, Leilei Du, Yang Li, De-Shen Liu, Weiwei An, Qinghua Cui, Weiping Li, Chun-Mei Cao
Zitieren
APA
Zhu, K., Guo, J., Liu, Y., Li, J., Wang, X., Dai, R., Wei, X., Jiang, D., Gao, L., Bai, J., Cao, R., Lin, Z., Zhou, W., Zhuang, Y., Wang, Y., Du, L., Li, Y., Liu, D. S., An, W., …, & Cao, C. M. (2026). TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion–Induced Myocardial Ferroptosis. Circulation, 153(17), 1314-1336. https://doi.org/10.1161/circulationaha.125.077782
Vancouver
Zhu K, Guo J, Liu Y, Li J, Wang X, Dai R, et al. TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion–Induced Myocardial Ferroptosis. Circulation. 2026;153(17):1314-1336. doi:10.1161/circulationaha.125.077782
BibTeX
@article{Zhu2026,
author = {Zhu, Kun and Guo, Jing and Liu, Yangli and Li, Jingchen and Wang, Xun and Dai, Rilei and Wei, Xiang and Jiang, Dingsheng and Gao, Le and Bai, Jiaxing and Cao, Rui and Lin, Zhiheng and Zhou, Wei and Zhuang, Yifan and Wang, Yufei and Du, Leilei and Li, Yang and Liu, De-Shen and An, Weiwei and Cui, Qinghua and Li, Weiping and Cao, Chun-Mei},
title = {TRIM28 Is an E3 Ligase of IRP2 Suppressing Ischemia/Reperfusion–Induced Myocardial Ferroptosis},
journal = {Circulation},
year = {2026},
volume = {153},
number = {17},
pages = {1314--1336},
doi = {10.1161/circulationaha.125.077782}
}
EUVIMED